Form 8-K - Current report:
SEC Accession No. 0001213900-25-051191
Filing Date
2025-06-04
Accepted
2025-06-04 16:30:08
Documents
12
Period of Report
2025-06-04
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0244011-8k_nektar.htm   iXBRL 8-K 25722
  Complete submission text file 0001213900-25-051191.txt   189340

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE nktr-20250604.xsd EX-101.SCH 3008
3 XBRL LABEL FILE nktr-20250604_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE nktr-20250604_pre.xml EX-101.PRE 22354
14 EXTRACTED XBRL INSTANCE DOCUMENT ea0244011-8k_nektar_htm.xml XML 3565
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 251023530
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)